According to a new study, the worldwide market for in vitro cancer
diagnosis will reach the $7.4 billion (€6.1 billion) mark by 2009,
as the demand for such tests will continue to increase as new
cancer cases soars toward the 10 million...
Researchers in the US have uncovered a contributing factor in
interferon resistance of malignant melanoma cells. The finding
represents a step forward in understanding of this type of cancer
and the changes in gene and cellular signalling...
EntreMed has entered into a research and development agreement with
the National Cancer Institute (NCI) to evaluate the role of
HIF-1alpha inhibition in the treatment of cancer. The agreement
aims to establish the relationship between...
US researchers have pinpointed a key molecule involved in
triggering rare but usually fatal cancers known as rhabdoid
tumours. This discovery could lead to novel therapies for these
tumours that mainly affect children.
The drug resistance encountered by scientists when treating cancer
cells has been the subject of research by German scientists who
believe they have identified a cellular protein, which mediates a
death signal.
Scientists have created the nanotechnology equivalent of a Trojan
horse to smuggle a powerful chemotherapeutic drug inside tumour
cells - increasing the drug's cancer-killing activity and reducing
its toxic side effects.
Scientists have reported that a molecule previously thought to play
a purely structural and inert role in cells may play a key role in
bringing about multidrug resistance in cancer.
Roche has started the roll-out its colorectal cancer treatment
Avastin (bevacizumab) - the first drug to reach the market that
works by inhibiting blood vessel formation in tumours - in Europe.
UK company Biocompatibles has teamed up with a microfluidics
specialist Q Chip to develop a system to improve the manufacture of
microspheres used in drug delivery and medical devices.
A widely used drug to treat breast cancer has been significantly
improved by the use of a new technology that binds it to albumin, a
common constituent of human blood.
Cancer treatment to kill tumours could be made more effective by a
revolutionary approach to angiogenesis which takes the unusual
approach of opening up the tumour blood supply allowing better
access for cancer drugs and more effective...
A 'tail' at one end of the Ubc 12 protein has been found to
play a key role in accelerating cell replication. The determination
of its structure and role bodes well for the development of new
types of drugs targeting the...
Researchers in the US have identified an interaction between a
known cancer-related gene and a cellular enzyme that could be the
target of a new generation of drugs aimed at cancer and parasitic
infections.
Scientists at Switzerland's Roche have developed a small molecule
that interferes with the binding of p53 - a protein that blocks the
development of cancer - to its natural inhibitor. The discovery
could open the door to novel,...
Danish biotech company T-cellic has just completed its second round
of financing, raising DK 40 million (€5.4m) in a deal that will set
the company up to take its T cell-based technologies, used for both
the localisation and treatment...
San-Diego based FeRx has received a slice of funding to support
research to evaluate the use of its MagneTarg drug delivery system
in the site-specific localisation of gemcitabine, a
chemotherapeutic agent already approved for the...
MolecularNature has forged a drug discovery partnership with Zetiq
Technologies that has already yielded a number of novel cancer
regulatory compounds.
A UK Phase I trial has been initiated for XR5944 (also known as
MLN944), a DNA targeting agent under evaluation for the treatment
of advanced cancers. The product is under development by USA-based
firm Millennium Pharmaceuticals and...
Canadian drug development company Ecopia BioSciences on Monday
announced that it had filed patent applications for the first two
novel compounds using its proprietary drug discovery platform -
suggesting investments by the company...
